Previous 10 | Next 10 |
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced the Company will partic...
Silence Therapeutics plc (Nasdaq: SLN) (“Silence” or the “Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced that Alistair Gray, wh...
2024-04-11 12:24:46 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biotech stocks can offer some of the most explosive, exciting opportunities on the market. That is, if you find the right one. Viking Therapeutics (NASDAQ: VKTX ) is the...
Published findings demonstrate zerlasiran was well-tolerated and significantly reduced Lp(a) after single and multiple dosing Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), an experienced and innovative biotechnology company committed to ...
2024-03-14 15:30:02 ET Chardan Capital analyst issues BUY recommendation for SLN on March 14, 2024 02:01PM ET. The previous analyst recommendation was Buy. SLN was trading at $24.62 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current ...
2024-03-13 17:30:02 ET H.C. Wainwright analyst issues BUY recommendation for SLN on March 13, 2024 04:01PM ET. The previous analyst recommendation was Buy. SLN was trading at $25.61 at issue of the analyst recommendation. The overall analyst consensus : HOLD. Current...
2024-03-13 10:01:09 ET Silence Therapeutics plc (SLN) Q4 2023 Earnings Conference March 13, 2024 08:00 AM ET Company Participants Gem Hopkins - Head of Investor Relations & Corporate Communications Craig Tooman - President & Chief Executive Officer Rhonda...
2024-03-13 10:00:21 ET More on Health Care Select Sector SPDR XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming Waters, Moderna most shorted ...
2024-03-13 08:53:09 ET More on Silence Therapeutics Silence Therapeutics plc 2023 Q4 - Results - Earnings Call Presentation Silence Therapeutics: Multiple 2024 Catalysts Make This mRNA Biotech Worth A Look Silence Therapeutics announces oversubscribed $120M private p...
2024-03-13 08:29:15 ET Read the full article on Seeking Alpha For further details see: KB Financial, BeiGene, Legend Biotech among premarket gainers' pack
News, Short Squeeze, Breakout and More Instantly...
Silence Therapeutics Plc Company Name:
SLN Stock Symbol:
NASDAQ Market:
Silence Therapeutics Plc Website:
2024-06-28 10:00:07 ET Keay Nakae from Chardan Capital issued a price target of $55.00 for SLN on 2024-06-28 08:03:00. The adjusted price target was set to $55.00. At the time of the announcement, SLN was trading at $19. The overall price target consensus is at $48.33 wi...
2024-06-28 09:00:06 ET Michael Ulz from Morgan Stanley issued a price target of $49.00 for SLN on 2024-06-28 07:44:00. The adjusted price target was set to $49.00. At the time of the announcement, SLN was trading at $19. The overall price target consensus is at $38.00 wi...
Divesiran eliminated the need for phlebotomy in all well-controlled patients following infrequent dosing and was well tolerated Data support advancing divesiran into Phase 2 Company to host conference call today at 8:30am Eastern Time Silence Therapeutics plc (“Si...